Lihong Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lihong Chen has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Jiandong Chen
Moffitt Cancer Center 1 Department of Molecular Oncology Tampa, Florida
20 shared publications - Bin Fang
Moffitt Cancer Center
11 shared publications - Ernst Schönbrunn
H. Lee Moffitt Cancer Center and Research Institute
11 shared publications - Justin M. Lopchuk
Drug Discovery Department, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, Florida 33612, United States
11 shared publications - Marianna Sansone
Molecular Oncology Department, Moffitt Cancer Center, Tampa, Florida
11 shared publications - Mingxiang Teng
H. Lee Moffitt Cancer Center & Research Institute
11 shared publications
Latest Publications
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S1 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S1. A1874 induces BRD4 degradation in cell lines with WT p53.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S1 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S1. A1874 induces BRD4 degradation in cell lines with WT p53.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Data from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Proteolysis-targeting chimeras (PROTAC) are bivalent molecules that simultaneously bind to proteins of interest and cellular ubiquitin E3 ligases to promote target degradation. Tumor-specific expression of E3 should increase therapeutic efficacy and reduce toxicity in cancer therapy applications. The E3 ligases currently employed during PROTAC design, such as CRBN, VHL, c-IAP, and MDM2, are ubiquitously expressed and not considered tumor-specific. However, MDM2 is part of the p53-negative feedback loop and is dynamically regulated at transcriptional and posttranslational levels. MDM2 gene amplification occurs at a frequency of 4% to 20% in multiple tumor types. To investigate whether MDM2 can serve as a tumor-specific PROTAC E3 in certain settings, we analyzed the benchmark compound A1874 (JQ1-Idasanutlin chimera targeting BRD4) under various conditions that affect MDM2 expression and activity. The results showed that A1874 activity is dependent on p53-mediated induction of MDM2 expression and is inactive in cells with mutant p53. Importantly, A1874 showed, on average, ∼12-fold higher potency in tumor cells with MDM2 amplification compared with nonamplified cells, correlating with enhanced cytotoxicity. The results suggest that tumors with MDM2 amplification or overexpression can be selectively targeted using the PROTAC approach.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Proteolysis-targeting chimeras (PROTAC) are bivalent molecules that simultaneously bind to proteins of interest and cellular ubiquitin E3 ligases to promote target degradation. Tumor-specific expression of E3 should increase therapeutic efficacy and reduce toxicity in cancer therapy applications. The E3 ligases currently employed during PROTAC design, such as CRBN, VHL, c-IAP, and MDM2, are ubiquitously expressed and not considered tumor-specific. However, MDM2 is part of the p53-negative feedback loop and is dynamically regulated at transcriptional and posttranslational levels. MDM2 gene amplification occurs at a frequency of 4% to 20% in multiple tumor types. To investigate whether MDM2 can serve as a tumor-specific PROTAC E3 in certain settings, we analyzed the benchmark compound A1874 (JQ1-Idasanutlin chimera targeting BRD4) under various conditions that affect MDM2 expression and activity. The results showed that A1874 activity is dependent on p53-mediated induction of MDM2 expression and is inactive in cells with mutant p53. Importantly, A1874 showed, on average, ∼12-fold higher potency in tumor cells with MDM2 amplification compared with nonamplified cells, correlating with enhanced cytotoxicity. The results suggest that tumors with MDM2 amplification or overexpression can be selectively targeted using the PROTAC approach.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S2 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S2. Rescue of mutant p53 function restores the activity of MDM2-recruiting PROTAC.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S2 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S2. Rescue of mutant p53 function restores the activity of MDM2-recruiting PROTAC.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S6 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S6. WT p53 function is required for efficient target degradation in MDM2 amplified cells by A1874.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S6 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S6. WT p53 function is required for efficient target degradation in MDM2 amplified cells by A1874.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S5 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S5. Relative MDM2 expression levels in cell lines.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S5 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S5. Relative MDM2 expression levels in cell lines.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S3 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S3. Chemotherapy drugs interfere with MDM2-dependent PROTAC activity by blocking MDM2 expression.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S3 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S3. Chemotherapy drugs interfere with MDM2-dependent PROTAC activity by blocking MDM2 expression.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Table 1. Correlation of A1874 activity with MDM2 and p53 status.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Table 1. Correlation of A1874 activity with MDM2 and p53 status.
- Open Access
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Supplemental Figure S4 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S4. MDM2 amplification in different tumor types.
- 1 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure S4 from MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Supplemental Figure S4. MDM2 amplification in different tumor types.
- 10 January 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (6) , 948-956
MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Proteolysis-targeting chimeras (PROTAC) are bivalent molecules that simultaneously bind to proteins of interest and cellular ubiquitin E3 ligases to promote target degradation. Tumor-specific expression of E3 should increase therapeutic efficacy and reduce toxicity in cancer therapy applications. The E3 ligases currently employed during PROTAC design, such as CRBN, VHL, c-IAP, and MDM2, are ubiquitously expressed and not considered tumor-specific. However, MDM2 is part of the p53-negative feedback loop and is dynamically regulated at transcriptional and posttranslational levels. MDM2 gene amplification occurs at a frequency of 4% to 20% in multiple tumor types. To investigate whether MDM2 can serve as a tumor-specific PROTAC E3 in certain settings, we analyzed the benchmark compound A1874 (JQ1-Idasanutlin chimera targeting BRD4) under various conditions that affect MDM2 expression and activity. The results showed that A1874 activity is dependent on p53-mediated induction of MDM2 expression and is inactive in cells with mutant p53. Importantly, A1874 showed, on average, ∼12-fold higher potency in tumor cells with MDM2 amplification compared with nonamplified cells, correlating with enhanced cytotoxicity. The results suggest that tumors with MDM2 amplification or overexpression can be selectively targeted using the PROTAC approach.
- 10 January 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 25 (6) , 948-956
MDM2 Amplification Enables Selective PROTAC Targeting of Tumor Cells
Proteolysis-targeting chimeras (PROTAC) are bivalent molecules that simultaneously bind to proteins of interest and cellular ubiquitin E3 ligases to promote target degradation. Tumor-specific expression of E3 should increase therapeutic efficacy and reduce toxicity in cancer therapy applications. The E3 ligases currently employed during PROTAC design, such as CRBN, VHL, c-IAP, and MDM2, are ubiquitously expressed and not considered tumor-specific. However, MDM2 is part of the p53-negative feedback loop and is dynamically regulated at transcriptional and posttranslational levels. MDM2 gene amplification occurs at a frequency of 4% to 20% in multiple tumor types. To investigate whether MDM2 can serve as a tumor-specific PROTAC E3 in certain settings, we analyzed the benchmark compound A1874 (JQ1-Idasanutlin chimera targeting BRD4) under various conditions that affect MDM2 expression and activity. The results showed that A1874 activity is dependent on p53-mediated induction of MDM2 expression and is inactive in cells with mutant p53. Importantly, A1874 showed, on average, ∼12-fold higher potency in tumor cells with MDM2 amplification compared with nonamplified cells, correlating with enhanced cytotoxicity. The results suggest that tumors with MDM2 amplification or overexpression can be selectively targeted using the PROTAC approach.
- Open Access
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Data from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
The bromodomain-containing protein, transcription factor IID subunit 1 (TAF1; transcription factor II-250), is the largest component of the multiprotein assembly transcription factor IID, a dynamic complex that serves as a general factor for transcription initiation. CRISPR and RNAi screens of pan-cancer cell lines revealed that TAF1 is broadly required for optimal cell growth and survival, but a subset of cell lines showed enhanced TAF1 dependence. These observations suggest that TAF1 has the potential to serve as a therapeutic target in sensitive tumors. Current approaches employed to target TAF1 are limited to monovalent small-molecule inhibitors of the bromodomain. However, recent studies showed that such inhibitors lack cancer cell kill potential. We applied a structure-guided approach to generate cereblon recruiting Proteolysis Targeting Chimera (PROTAC) degraders of TAF1 using the chemical scaffolds of ceralasertib and GNE371. We present evidence that GNE371-based PROTACs are effective in degradation of TAF1 at concentrations as low as 1 nmol/L. TAF1 depletion activated p53 and induced apoptosis in acute myeloid leukemia (AML) cell lines and certain solid tumor cells. An in vivo active TAF1 PROTAC inhibited the growth of AML tumor xenografts. The results showed that inhibition of the bromodomain is not sufficient to inactivate TAF1 functions, whereas a PROTAC approach induces strong biological effects. Furthermore, TAF1 PROTACs have therapeutic potential against AML and other sensitive tumors.
- 3 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from PROTAC-Mediated Degradation of TAF1 Induces Apoptosis in AML Cells and Inhibits Tumor Growth In Vivo
The bromodomain-containing protein, transcription factor IID subunit 1 (TAF1; transcription factor II-250), is the largest component of the multiprotein assembly transcription factor IID, a dynamic complex that serves as a general factor for transcription initiation. CRISPR and RNAi screens of pan-cancer cell lines revealed that TAF1 is broadly required for optimal cell growth and survival, but a subset of cell lines showed enhanced TAF1 dependence. These observations suggest that TAF1 has the potential to serve as a therapeutic target in sensitive tumors. Current approaches employed to target TAF1 are limited to monovalent small-molecule inhibitors of the bromodomain. However, recent studies showed that such inhibitors lack cancer cell kill potential. We applied a structure-guided approach to generate cereblon recruiting Proteolysis Targeting Chimera (PROTAC) degraders of TAF1 using the chemical scaffolds of ceralasertib and GNE371. We present evidence that GNE371-based PROTACs are effective in degradation of TAF1 at concentrations as low as 1 nmol/L. TAF1 depletion activated p53 and induced apoptosis in acute myeloid leukemia (AML) cell lines and certain solid tumor cells. An in vivo active TAF1 PROTAC inhibited the growth of AML tumor xenografts. The results showed that inhibition of the bromodomain is not sufficient to inactivate TAF1 functions, whereas a PROTAC approach induces strong biological effects. Furthermore, TAF1 PROTACs have therapeutic potential against AML and other sensitive tumors.